Leerink Partners Cuts Price Target on Allergan (AGN) Following New U.S. Treasury Regulations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
Allergan Reiterates Strong Standalone Growth Profile and Strategy Following Termination of Pfizer Transaction
April 6, 2016 6:45 AM EDTDUBLIN, April 6, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced that its merger agreement with Pfizer (NYSE: PFE) has been terminated by mutual agreement, effective today. In connection with the termination of the merger agreement, Pfizer has agreed to pay Allergan $150 million for reimbursement of expenses associated with the transaction.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
Allergan reiterated its compelling standalone growth profile and strategy following the... More
Pfizer Announces Termination of Proposed Combination with Allergan
April 6, 2016 6:45 AM EDTNEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an Adverse Tax Law Change under the merger agreement.
Pfizer approached this transaction from a position of strength and viewed the potential combination as an accelerator of existing strategies, stated Ian Read, Chairman and Chief Executive... More
Pfizer and Allergan Issue Statement
April 4, 2016 7:05 PM EDTNEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Allergan plc (NYSE: AGN) today issued the following statement regarding the recently issued Department of Treasury Notice:
We are conducting a review of the U.S. Department of Treasurys actions announced today. Prior to completing the review, we wont speculate on any potential impact.
NO OFFER OR SOLICITATION
This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an... More
